Funds · 13F filer · New York, NY

Casdin Capital, LLC

$2.0B in 43 U.S. stocks and ETFs at the end of June 30, 2026, as reported to the SEC.1

1y return+88.8%S&P 500 +20.9%
3y return+80.6%S&P 500 +68.5%
5y return−38.3%S&P 500 +74.5%

These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.

$100 invested in its stock picks

Since December 31, 2019: $97 against $232 in the S&P 500.2

Casdin Capital, LLCS&P 500 (SPY)
$44$100$23220192026

Top holdings

At the end of June 30, 2026. Change is in shares since the quarter before.2

StockValueShare of portfolioChange
RVMDRevolution Medicines Inc$482.7M24.2%
RLAYRelay Therapeutics Inc$300.0M15.0%+11.2%
WGSGenedx Holdings Corp$254.5M12.7%+23.3%
Biolife Solutions IncCUSIP 09062W204$131.5M6.6%−21.9%
ILMNIllumina Inc$93.2M4.7%
LABStandard Biotools Inc$73.0M3.7%
GPCRStructure Therapeutics Inc$63.1M3.2%
DNLIDenali Therapeutics Inc$52.6M2.6%+11.1%
NGNENeurogene Inc$48.6M2.4%+8.8%
BEAMBeam Therapeutics Inc$46.3M2.3%
TXG10x Genomics Inc$40.3M2.0%−53.8%
SRRKScholar Rock Hldg Corp$36.6M1.8%+90.0%
PSNLPersonalis Inc$34.2M1.7%+59.4%
GRALGrail Inc$32.8M1.6%+108.7%
GHGuardant Health Inc$27.8M1.4%−41.3%
MAZEMaze Therapeutics Inc$25.2M1.3%+11.2%
HIMSHims & Hers Health Inc$24.3M1.2%
ALNYAlnylam Pharmaceuticals Inc$22.6M1.1%
TSHATaysha Gene Therapies Inc$22.1M1.1%
AGMBAgomab Therapeutics Nv$20.1M1.0%
SEPNSepterna Inc$18.5M0.9%
PBLSParabilis Medicines Inc$17.7M0.9%New
SIONSionna Therapeutics Inc$17.6M0.9%New
VCYTVeracyte Inc$16.2M0.8%
ANLAdlai Nortye Ltd$14.4M0.7%+132.1%

Best picks still held

How each current holding has done since the quarter it first appeared in its filings (up to six years back).

StockHeld sinceReturn sinceNow worth
RVMDRevolution Medicines IncJune 30, 2020+493.2%$482.7M
GHGuardant Health IncJune 30, 2024+419.5%$27.8M
MAZEMaze Therapeutics IncMarch 31, 2025+171.0%$25.2M
VCYTVeracyte IncMarch 31, 2024+165.0%$16.2M
TXG10x Genomics IncDecember 31, 2025+135.1%$40.3M
GPCRStructure Therapeutics IncMarch 31, 2023+125.6%$63.1M
PSNLPersonalis IncMarch 31, 2026+110.4%$34.2M
ALNYAlnylam Pharmaceuticals IncJune 30, 2020+103.2%$22.6M
Biolife Solutions IncCUSIP 09062W204June 30, 2020+72.7%$131.5M
ANLAdlai Nortye LtdMarch 31, 2026+66.2%$14.4M

Sold off last quarter

  • Qiagen NvCUSIP N72482156 was $14.4M
  • TEMTempus Ai Inc was $13.3M
  • MLTXMoonlake Immunotherapeutics was $8.4M

Quarter by quarter

QuarterIts picksS&P 500
June 30, 2026+46.5%+14.8%
March 31, 2026−17.1%−4.6%
December 31, 2025+28.1%+2.4%
September 30, 2025+21.4%+7.8%
June 30, 2025+8.1%+10.5%
March 31, 2025−18.0%−4.6%
December 31, 2024−1.3%+2.1%
September 30, 2024+10.6%+5.4%
June 30, 2024+1.6%+4.0%
March 31, 2024+10.3%+10.0%
December 31, 2023+7.9%+11.2%
September 30, 2023−18.2%−3.6%
June 30, 2023+0.3%+8.3%
March 31, 2023−2.8%+7.0%
December 31, 2022−17.9%+7.1%
September 30, 2022+23.2%−5.3%
June 30, 2022−29.5%−16.5%
March 31, 2022−29.8%−4.9%
December 31, 2021−17.1%+10.7%
September 30, 2021−15.5%+0.3%

Sources

Every number on this page points here. Each one links to the public record.

  1. 1
    CIK 1534261
  2. 2
    Filed August 14, 2026 · accession 0000919574-26-005491